Map4k1 inhibitors
AssigneeBlueprint Medicines Corporation
InventorsJason D. Brubaker, Michael J. Burke, Joshua T. Close, Thomas A. Dineen, Chandrasekhar V. Miduturu, Emanuele Perola
Life of this patent
Estimating the term…
Abstract
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.
Claims27
A compound of Formula I
- or a pharmaceutically acceptable salt thereof,
- wherein:
- T is selected from
- -L1-C(O)—NR11R12, -L1-O—C(O)—NR11R12 and -L2-NR13—C(O)—R14;
- Ring A is C4-6 cycloalkyl or 4-6 membered heterocycle containing nitrogen, wherein said cycloalkyl or heterocycle is optionally substituted with 1-2 R6;
- each R6 is independently selected from CH3, methoxy, CF3, CH2F, and CHF2;
- L1 and L2 are each independently selected from C1-C3 alkylene optionally substituted with 1-2 R15;
- each s is independently selected from 1, 2, and 3;
- B is O or NH;
- Q is N or CH;
- x is 0, 1, or 2;
- R1 and R2 are each independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, and 4 to 6-membered heterocycle, wherein said alkyl is optionally substituted with 1-2 R3;
- each R3 is independently selected from halogen, hydroxyl and OR4;
- or
- each R4 is independently selected from C1-3 alkyl, CF3, CH2F, and CHF2;
- each R5 is independently selected from C1-2 alkyl, CF3, CH2F, and CHF2, or
- two R5 attached to the same carbon atom taken together with the carbon atom to which they attach form C3-5 cycloalkyl;
- or two R5 attached to two adjacent carbon atoms taken together with the two adjacent carbon atoms to which they attach form C4-6 cycloalkyl;
- n is 0, 1, 2, 3, or 4;
- R7 is selected from C1-3 alkyl, C3-6 cycloalkyl, OC1-4 alkyl, NR9R10, and 3-5 membered heterocycle containing nitrogen or oxygen, wherein said alkyl, cycloalkyl, or heterocycle is optionally substituted with 1-3 R8;
- each R8 is independently selected from halogen, C1-3 alkyl, CF3, CH2F, CHF2, hydroxyl, OC1-3 alkyl, OCF3, OCH2F, and OCHF2;
- R9 is selected from C1-2 alkyl;
- R10 is selected from C1-2 alkyl
- R11 is selected from C1-3alkyl;
- R12 is selected from C1-3 alkyl;
- or R11 and R12 taken together with the nitrogen atom to which they attach form 4 to 6-membered heterocycle containing nitrogen;
- R13 is H or C1-2alkyl;
- R14 is C1-3alkyl, or R13 and R14 taken together with the atoms to which attach form 4 to 6-membered heterocycle containing nitrogen;
- and
- each R15 is independently selected from halogen, methoxy, and C1-2alkyl, or two R15 taken together with the two adjacent carbon atoms to which they attach form cyclopropyl.
-8. (canceled)
-13. (canceled)
-16. (canceled)
-20. (canceled)
-28. (canceled)
A compound of Table 1 or a pharmaceutically acceptable salt thereof.
-32. (canceled)
-37. (canceled)
Dependencies are inferred from the claim text.